Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

Amgen Grant To Study Treatments For Older Leukemia Patients Received By Loyola Fellow

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Seniors / Aging;  Stem Cell Research;  Blood / Hematology
Article Date: 06 Jun 2009 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Dr. Aileen Go of Loyola University Health System, who is studying treatment options for older leukemia and lymphoma patients, has won a prestigious Amgen Foundation Fellowship grant.

Go, a second-year fellow in hematology/oncology, will work with Dr. Patrick Stiff, director of Loyola's Cardinal Bernardin Cancer Center. Stiff and Go are studying the use of umbilical cord blood transplants grown from cord blood cells outside the body. The transplants are intended for patients ages 55 to 75, who previously have been excluded from such treatments.

Patients will receive high-dose chemotherapy, which, in addition to killing cancer cells also destroys the patient's immune system cells. To build a new immune system, patients receive transplanted stem cells, which develop into new immune system cells.

Older patients generally cannot tolerate high-dose chemotherapy. Go and Stiff will study a reduced-intensity chemotherapy regimen, as well as a method for boosting the number of stem cells.

The stem cells will come from donated umbilical cord blood. A newborn's cord blood does not contain enough stem cells for most adult patients. So the cord blood will be sent to a lab that will grow more stem cells prior to the transplant.

The Amgen Foundation provides grants for such purposes as advancing science education and improving the quality of care and access for patients. The one-year award that Go received is given to medical researchers who are beginning to pursue academic careers.

"These are very competitive, with the majority of the awards going to MDs and PhDs who submit truly amazing projects for funding," Stiff said.

Dr. Paul Whelton, president and CEO of Loyola University Health System, added that Loyola is "a home for the next generation of leaders -- those who will make a difference in reducing the burden of illness in society."

Source:
Jim Ritter
Loyola University Health System


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Chemotherapy? What Are The Side Effects Of Chemotherapy?
22 Jul 2009
Chemotherapy is the use of chemicals (medication) to treat disease - more specifically, it usually refers to the destruction of cancer cells. However, chemotherapy also includes the use of antibiotics or other medications to treat any disease...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...